Lion TCR
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- $72M
Investors
- 11
About Lion TCR
Founded in 2016 and based in Singapore, Lion TCR Pte., trading as Lion TCR, is a biotechnology company dedicated to the development and commercialization of our TCR-T therapy. In November 2022, it announces a Poster Presentation of the Phase 1 Study for LioCyx-M at AASLD The Liver Meeting. Xiaoming Peng is the CEO of the company, graduated from the National University of Singapore, and has over 18 years of working experience at A*STAR. Lion TCR uses TCR-T cells for clinical trials against liver cancer to evaluate the safety and effectiveness of TCR-T cell therapy in clinical practice. The company has developed an autologous T-cell product LioCyx-M which is transferred with mRNA encoding HBV antigen-specific TCR, and it has been used clinically for the treatment of HBV-related liver cancer and recurrent HBV-related liver cancer post-liver transplant. The company's revenue is generated by conducting ongoing clinical trials against hepatocellular carcinoma.
Who invested in Lion TCR
11 investors across 4 rounds
See all investors in Lion TCR
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Lion TCR
Who invested in Lion TCR?
Lion TCR has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lion TCR raised?
Lion TCR has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Lion TCR last raise money?
Lion TCR's most recent round on record is a Series B, in Jan 2026.
What does Lion TCR do?
Founded in 2016 and based in Singapore, Lion TCR Pte.
Where is Lion TCR headquartered?
Lion TCR is headquartered in Singapore, Singapore.
Which VCs invest in companies like Lion TCR?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Lion TCR's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Lion TCR? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.